These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
359 related articles for article (PubMed ID: 28844076)
1. Synaptic Loss and the Pathophysiology of PTSD: Implications for Ketamine as a Prototype Novel Therapeutic. Krystal JH; Abdallah CG; Averill LA; Kelmendi B; Harpaz-Rotem I; Sanacora G; Southwick SM; Duman RS Curr Psychiatry Rep; 2017 Aug; 19(10):74. PubMed ID: 28844076 [TBL] [Abstract][Full Text] [Related]
2. Ketamine for post-traumatic stress disorders and it's possible therapeutic mechanism. Asim M; Wang B; Hao B; Wang X Neurochem Int; 2021 Jun; 146():105044. PubMed ID: 33862176 [TBL] [Abstract][Full Text] [Related]
3. The emergence of ketamine as a novel treatment for posttraumatic stress disorder. Feder A; Rutter SB; Schiller D; Charney DS Adv Pharmacol; 2020; 89():261-286. PubMed ID: 32616209 [TBL] [Abstract][Full Text] [Related]
4. Effects of systemic glutamatergic manipulations on conditioned eyeblink responses and hyperarousal in a rabbit model of post-traumatic stress disorder. Burhans LB; Smith-Bell CA; Schreurs BG Behav Pharmacol; 2017 Oct; 28(7):565-577. PubMed ID: 28799954 [TBL] [Abstract][Full Text] [Related]
5. The Neurobiology and Pharmacotherapy of Posttraumatic Stress Disorder. Abdallah CG; Averill LA; Akiki TJ; Raza M; Averill CL; Gomaa H; Adikey A; Krystal JH Annu Rev Pharmacol Toxicol; 2019 Jan; 59():171-189. PubMed ID: 30216745 [TBL] [Abstract][Full Text] [Related]
6. Glutamate dysregulation and glutamatergic therapeutics for PTSD: Evidence from human studies. Averill LA; Purohit P; Averill CL; Boesl MA; Krystal JH; Abdallah CG Neurosci Lett; 2017 May; 649():147-155. PubMed ID: 27916636 [TBL] [Abstract][Full Text] [Related]
7. Continuous Ketamine Infusion for Pain as an Opportunity for Psychotherapy for PTSD: A Case Series of Ketamine-Enhanced Psychotherapy for PTSD and Pain (KEP-P2). Keizer BM; Roache JD; Jones JR; Kalpinski RJ; Porcerelli JH; Krystal JH Psychother Psychosom; 2020; 89(5):326-329. PubMed ID: 32248200 [No Abstract] [Full Text] [Related]
11. Ketamine, at a dose that disrupts motor behavior and latent inhibition, enhances prefrontal cortex synaptic efficacy and glutamate release in the nucleus accumbens. Razoux F; Garcia R; Léna I Neuropsychopharmacology; 2007 Mar; 32(3):719-27. PubMed ID: 16525415 [TBL] [Abstract][Full Text] [Related]
12. Remission From Behavioral Dysregulation in a Child With PTSD After Receiving Procedural Ketamine. Donoghue AC; Roback MG; Cullen KR Pediatrics; 2015 Sep; 136(3):e694-6. PubMed ID: 26260717 [TBL] [Abstract][Full Text] [Related]
13. Ketamine promotes increased freezing behavior in rats with experimental PTSD without changing brain glucose metabolism or BDNF. Saur L; Neves LT; Greggio S; Venturin GT; Jeckel CMM; Costa Da Costa J; Bertoldi K; Schallenberger B; Siqueira IR; Mestriner RG; Xavier LL Neurosci Lett; 2017 Sep; 658():6-11. PubMed ID: 28823895 [TBL] [Abstract][Full Text] [Related]
14. Differential regulation of GluA1 expression by ketamine and memantine. Zhang K; Yamaki VN; Wei Z; Zheng Y; Cai X Behav Brain Res; 2017 Jan; 316():152-159. PubMed ID: 27599619 [TBL] [Abstract][Full Text] [Related]
15. A fast synaptic potential mediated by NMDA and non-NMDA receptors. Wolszon LR; Pereda AE; Faber DS J Neurophysiol; 1997 Nov; 78(5):2693-706. PubMed ID: 9356419 [TBL] [Abstract][Full Text] [Related]
16. Exploring a post-traumatic stress disorder paradigm in Flinders sensitive line rats to model treatment-resistant depression II: response to antidepressant augmentation strategies. Brand SJ; Harvey BH Acta Neuropsychiatr; 2017 Aug; 29(4):207-221. PubMed ID: 27692010 [TBL] [Abstract][Full Text] [Related]
17. Ketamine accelerates fear extinction via mTORC1 signaling. Girgenti MJ; Ghosal S; LoPresto D; Taylor JR; Duman RS Neurobiol Dis; 2017 Apr; 100():1-8. PubMed ID: 28043916 [TBL] [Abstract][Full Text] [Related]
18. Rapastinel (GLYX-13) has therapeutic potential for the treatment of post-traumatic stress disorder: Characterization of a NMDA receptor-mediated metaplasticity process in the medial prefrontal cortex of rats. Burgdorf J; Kroes RA; Zhang XL; Gross AL; Schmidt M; Weiss C; Disterhoft JF; Burch RM; Stanton PK; Moskal JR Behav Brain Res; 2015 Nov; 294():177-85. PubMed ID: 26210936 [TBL] [Abstract][Full Text] [Related]